Stenocare

0,89

DKK

-1,66 %

STENO

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Mindre end 1K følgere

-1,66%

+22,57%

+22,57%

-2,84%

-57,62%

-36,52%

-87,21%

-92,22%

-93,48%

Stenocare er aktiv i sundhedsbranchen. Virksomheden har specialiseret sig i udviklingen af medicinsk cannabis. Stenocare er en af de første spillere, der er begyndt at sælge medicinske cannabisolier i Danmark. I fremtiden vil virksomheden også vende sig til andre europæiske markeder med sit produktsortiment. Stenocares har sit hovedkontor med beliggenhed i Randers.

Markedsværdi

53,97 mio. DKK

Aktieomsætning

36,13 t DKK

Omsætning

6,92 mio.

EBIT %

-230,49 %

P/E

-

Udbytteafkast, %

-

Finanskalender

27.2

2025

Årsrapport '24

8.5

2025

Delårsrapport Q1'25

21.8

2025

Delårsrapport Q2'25

ViserAlle indholdstyper

Selskabsmeddelelsefor 9 timer siden

STENOCARE A/S: Conditional Rights Issue subscribed to 45.0 percent

Pressemeddelelse20.1.2025, 11.29

STENOCARE - Final deadline for Subscription to New Shares at DKK 0.50 Each

Pressemeddelelse17.1.2025, 07.00

STENOCARE - Final deadline Soon for Subscription to New Shares at DKK 0.50 Each

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Pressemeddelelse15.1.2025, 10.57

STENOCARE - The new innovative ASTRUM 10-10 product is now available for German patients

Pressemeddelelse15.1.2025, 07.00

STENOCARE - Deadline Soon for Subscription to New Shares at DKK 0.50 Each

Pressemeddelelse15.1.2025, 07.00

STENOCARE - Deadline for tegning af nye aktier til 0,50 kr. pr. stk. nærmer sig

Pressemeddelelse10.1.2025, 16.03

STENOCARE A/S announces guarantee commitments in ongoing rights issue

Pressemeddelelse9.1.2025, 19.02

STENOCARE - Deadline for tegning af nye aktier til 0,50 kr. pr. stk. nærmer sig

Pressemeddelelse9.1.2025, 18.55

STENOCARE - Deadline soon to subscribe for new shares at DKK 0.50 each

Pressemeddelelse7.1.2025, 10.22

STENOCARE A/S: The subscription period in Stenocare's conditional rights issue begins today for the time limited offer of DKK 0,50 per new share

Pressemeddelelse3.1.2025, 10.21

STENOCARE's Innovative ASTRUM 10-10 Product Now Available for Norwegian Patients

Selskabsmeddelelse18.12.2024, 18.00

STENOCARE A/S: Conditional Rights Issue of up to 20.2 mDKK

Selskabsmeddelelse18.12.2024, 12.37

Communiqué from extraordinary general meeting in STENOCARE

Pressemeddelelse17.12.2024, 07.00

STENOCARE Gains Danish Approval for New Medical Cannabis CBD100 oil

Pressemeddelelse10.12.2024, 14.38

STENOCARE 3.0 Strategy: Management Shares Insights in Exclusive Interview with Proinvestor.com

Pressemeddelelse2.12.2024, 07.00

STENOCARE - Innovative New ASTRUM Product Officially Approved for Sale in Norway

Pressemeddelelse28.11.2024, 21.14

STENOCARE Celebrates Denmark's Permanent Legalisation of Medical Cannabis

Selskabsmeddelelse26.11.2024, 16.46

STENOCARE 3.0: Shifting Strategy to Focus on Trading and exit from Production

Selskabsmeddelelse26.11.2024, 16.11

Notice to Extraordinary General Meeting in STENOCARE A/S

Pressemeddelelse19.11.2024, 12.36

STENOCARE Hylder Den Danske Sundhedsministers Beslutning om Permanent Legalisering af Medicinsk Cannabis

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.